Published in Clin Infect Dis on November 01, 1998
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev (1999) 5.84
Virulence-related surface glycoproteins in the yeast pathogen Candida glabrata are encoded in subtelomeric clusters and subject to RAP1- and SIR-dependent transcriptional silencing. Genes Dev (2003) 1.94
Candida infections of the genitourinary tract. Clin Microbiol Rev (2010) 1.90
Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev (2004) 1.48
Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob Agents Chemother (2004) 1.46
Tn7-based genome-wide random insertional mutagenesis of Candida glabrata. Genome Res (2003) 1.36
Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc (2011) 1.28
Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges. Clin Microbiol Rev (2004) 1.22
Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine. Infect Immun (2002) 1.08
Transcriptomic analysis of vulvovaginal candidiasis identifies a role for the NLRP3 inflammasome. MBio (2015) 0.99
Prevalence of Candida species, including Candida dubliniensis, in Singapore. J Clin Microbiol (2003) 0.83
A genomewide screen in Schizosaccharomyces pombe for genes affecting the sensitivity of antifungal drugs that target ergosterol biosynthesis. Antimicrob Agents Chemother (2012) 0.82
Mucosal immunity in the female genital tract, HIV/AIDS. Biomed Res Int (2014) 0.81
UPC2A is required for high-level azole antifungal resistance in Candida glabrata. Antimicrob Agents Chemother (2014) 0.77
A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med (1989) 10.98
Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med (1984) 6.11
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med (1977) 5.86
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev (1999) 5.84
PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol (1997) 5.76
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Vibrio cholerae enterotoxin and its mode of action. Bacteriol Rev (1971) 4.98
Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med (1989) 4.72
One or more bound planets per Milky Way star from microlensing observations. Nature (2012) 4.68
Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol (2000) 4.26
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med (1991) 4.20
Transmission of the human immunodeficiency virus. N Engl J Med (1987) 4.17
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr (1999) 4.15
Experimental canine cholera. I. Development of the model. J Infect Dis (1969) 4.02
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol (1991) 3.99
Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol (1985) 3.97
Site and characteristics of electrolyte loss and effect of intraluminal glucose in experimental canine cholera. J Clin Invest (1968) 3.72
Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med (1983) 3.67
The outer boundary of the cytoskeleton: a lamina derived from plasma membrane proteins. Cell (1979) 3.66
Effects of HIV antibody test knowledge on subsequent sexual behaviors in a cohort of homosexually active men. Am J Public Health (1988) 3.66
An enterotoxin produced by noncholera vibrios. Johns Hopkins Med J (1972) 3.54
Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med (1999) 3.37
Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis (1990) 3.19
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother (1997) 3.17
Deactivation of cholera toxin by ganglioside. J Infect Dis (1971) 3.16
Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med (2000) 3.15
Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect Immun (1984) 3.07
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol (2000) 2.97
Reliability of self-reported sexual behavior risk factors for HIV infection in homosexual men. Public Health Rep (1988) 2.93
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Diagnosis of Trichomonas vaginalis infection by PCR using vaginal swab samples. J Clin Microbiol (1998) 2.81
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 2.69
Infection with the human immunodeficiency virus in prisoners: meeting the health care challenge. Am J Med (1993) 2.68
Vibriocidal and agglutinating antibody patterns in cholera patients. J Infect Dis (1966) 2.67
Intravenous drug abusers and the acquired immunodeficiency syndrome (AIDS). Demographic, drug use, and needle-sharing patterns. Arch Intern Med (1985) 2.62
Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS (2000) 2.61
The etiology of genital ulcer disease by multiplex polymerase chain reaction and relationship to HIV infection among patients attending sexually transmitted disease clinics in Pune, India. Sex Transm Dis (1999) 2.57
HIV infection in women in the United States: status at the Millennium. JAMA (2001) 2.51
Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis (2001) 2.51
Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis (2001) 2.49
Phylogenetic comparative analysis and the secondary structure of ribonuclease P RNA--a review. Gene (1989) 2.45
Nonadherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community-based HIV primary care clinic. AIDS Care (2005) 2.42
The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG (2011) 2.41
Knowledge of HIV antibody status and decisions to continue or terminate pregnancy among intravenous drug users. JAMA (1989) 2.41
Lack of transmission of HTLV-III/LAV infection to household contacts of patients with AIDS or AIDS-related complex with oral candidiasis. N Engl J Med (1986) 2.40
Effects of prostaglandins, theophylline, and cholera exotoxin upon transmucosal water and electrolyte movement in the canine jejunum. Gastroenterology (1971) 2.39
Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med (1992) 2.36
Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy. Am J Med (1986) 2.33
Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA (1992) 2.32
The deamination of cytidine and cytosine by acidic buffer solutions. Mutagenic implications. Biochemistry (1966) 2.30
Adherence of Candida albicans to human vaginal and buccal epithelial cells. J Infect Dis (1981) 2.27
Effect of Escherichia coli on fluid transport across canine small bowel. Mechanism and time-course with enterotoxin and whole bacterial cells. J Clin Invest (1973) 2.25
Survival differences in patients with AIDS. J Acquir Immune Defic Syndr (1991) 2.23
Anal sex among HIV-seronegative women at high risk of HIV exposure. The HIVNET Vaccine Preparedness Study 2 Protocol Team. J Acquir Immune Defic Syndr (2000) 2.22
Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoattraction. Cell (2001) 2.20
Bacterial vaginosis and HIV seroprevalence among female commercial sex workers in Chiang Mai, Thailand. AIDS (1995) 2.19
High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA (1992) 2.19
Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 2.15
Nosocomial Pseudomonas cepacia infection associated with chlorhexidine contamination. Am J Med (1982) 2.14
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr (2001) 2.13
Comparison of restriction enzyme analysis and pulsed-field gradient gel electrophoresis as typing systems for Candida albicans. J Clin Microbiol (1991) 2.12
Small bowel morphology in experimental canine cholera. A light and electron microscopic study. Lab Invest (1970) 2.12
Hierarchical pattern of mucosal candida infections in HIV-seropositive women. Am J Med (1990) 2.11
Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun (1993) 2.08
Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol (1996) 2.07
Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA (1996) 2.07
Streptococcus bovis septicemia and carcinoma of the colon. Ann Intern Med (1979) 2.06
Alopecia associated with fluconazole therapy. Ann Intern Med (1995) 2.05
Use of an on-line pager system to increase adherence to antiretroviral medications. AIDS Care (2003) 2.04
Factitious HIV syndrome in young women. AIDS Read (2001) 2.03
Hit HIV-1 hard, but only when necessary. Lancet (2000) 1.98
The discipline of teams. Harv Bus Rev (1993) 1.97
Molecular analysis of cytoplasmic microtubules in situ: identification of both widespread and specific proteins. Cell (1981) 1.94
Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Ann Intern Med (1993) 1.92
Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial. Clin Infect Dis (2011) 1.92
Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev (1996) 1.90
Seroepidemiology of human T-lymphotropic virus type III among homosexual men with the acquired immunodeficiency syndrome or generalized lymphadenopathy and among asymptomatic controls in Boston. Ann Intern Med (1985) 1.89
Human T-lymphotropic virus type III in high-risk, antibody-negative homosexual men. Ann Intern Med (1986) 1.88
Risk factors for second urinary tract infection among college women. Am J Epidemiol (2000) 1.88
Experimental cholera. A canine model. Lancet (1966) 1.88
Scaphoid malunion. J Hand Surg Am (1989) 1.87
HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol (2005) 1.86
T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis (1997) 1.85
Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect (2001) 1.85
Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun (1993) 1.84
HIV testing, counseling, and prophylaxis after sexual assault. JAMA (1994) 1.83
Screening immigrants and international travelers for the human immunodeficiency virus. N Engl J Med (1990) 1.81
Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis (1993) 1.81
Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med (1986) 1.81
Characterization of a lysine-specific active transport system in Rickettsia prowazeki. J Bacteriol (1977) 1.80